Equities research analysts expect that Inovalon Holdings Inc (NASDAQ:INOV) will report $106.88 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for Inovalon’s earnings. The lowest sales estimate is $101.30 million and the highest is $110.20 million. Inovalon reported sales of $108.31 million in the same quarter last year, which would suggest a negative year over year growth rate of 1.3%. The business is scheduled to issue its next earnings results on Wednesday, May 2nd.
On average, analysts expect that Inovalon will report full-year sales of $106.88 million for the current fiscal year, with estimates ranging from $468.40 million to $472.10 million. For the next financial year, analysts anticipate that the firm will report sales of $512.50 million per share, with estimates ranging from $492.50 million to $531.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover Inovalon.
Inovalon (NASDAQ:INOV) last released its quarterly earnings data on Tuesday, February 20th. The technology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). The company had revenue of $114.60 million during the quarter, compared to analyst estimates of $116.83 million. Inovalon had a net margin of 7.51% and a return on equity of 4.79%. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.05 EPS.
Shares of Inovalon (NASDAQ:INOV) opened at $11.75 on Monday. The company has a market capitalization of $1,710.00, a P/E ratio of 90.38, a PEG ratio of 3.33 and a beta of 0.96. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.32. Inovalon has a twelve month low of $10.99 and a twelve month high of $17.80.
In related news, insider Shauna L. Vernal sold 44,270 shares of the stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $14.00, for a total value of $619,780.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 48.28% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. FNY Managed Accounts LLC bought a new position in Inovalon during the 4th quarter worth $150,000. Creative Planning bought a new position in Inovalon during the 4th quarter worth $152,000. Teacher Retirement System of Texas bought a new position in Inovalon during the 4th quarter worth $294,000. Macquarie Group Ltd. increased its position in Inovalon by 877.8% during the 4th quarter. Macquarie Group Ltd. now owns 26,400 shares of the technology company’s stock worth $396,000 after buying an additional 23,700 shares during the period. Finally, Smith Asset Management Group LP bought a new position in Inovalon during the 4th quarter worth $436,000. Hedge funds and other institutional investors own 27.64% of the company’s stock.
Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.